证券代码：688351 证券简称：微电生理 公告编号：2023-018 上海微创电生理医疗科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海微创电生理医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日召开第三届董事会第四次会议、第三届监事会第四次会议，审议通过了 《关于使用暂时闲置募集资金进行现金管理的议案》，同意公司拟使用不超过 85,000 万元（含本数）的暂时闲置募集资金（含超募资金）进行现金管理，用于 购买安全性高、流动性好的理财产品或存款类产品，使用期限自公司董事会审议 通过之日起 12 个月内有效。具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海微创电生理医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1587 号）核准，公司向社会 公开发行人民币普通股（A 股）7,060 万股，发行价格为 16.51 元/股，募集资金 总额为人民币 116,560.60 万元，扣除发行费 ...

核查意见 华泰联合证券有限责任公司关于 上海微创电生理医疗科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）作 为上海微创电生理医疗科技股份有限公司（以下简称"微电生理"或"公司"） 首次公开发行股票并在科创板上市的保荐人及持续督导机构，根据《证券发行上 市保荐业务管理办法》《科创板上市公司持续监管办法（试行）》《上海证券交 易所科创板股票上市规则（2020 年 12 月修订）》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求（2022 年修订）》等相关法律、法规和规范 性文件的规定，对微电生理使用部分闲置募集资金（含超募资金）进行现金管理 的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海微创电生理医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1587 号）核准，公司向社会 公开发行人民币普通股（A 股）7,060 万股，发行价格为 16.51 元/股，募集资金 总额为人民币 ...

核查意见 华泰联合证券有限责任公司关于 上海微创电生理医疗科技股份有限公司 部分募投项目增加实施主体的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）作 为上海微创电生理医疗科技股份有限公司（以下简称"微电生理"或"公司"） 首次公开发行股票并在科创板上市的保荐人及持续督导机构，根据《证券发行上 市保荐业务管理办法》《上海证券交易所科创板股票上市规则（2020 年 12 月修 订）》及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相 关法律、法规和规范性文件的规定，对公司增加部分募投项目实施主体的事项进 行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海微创电生理医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1587 号）核准，公司向社会 公开发行人民币普通股（A 股）7,060 万股，发行价格为 16.51 元/股，募集资金 总额为人民币 116,560.60 万元，扣除发行费用 9,572.61 万元后，实际募集资金净 额为 106,987.99 万元。上述募集资金实际到位时间为 2022 年 8 月 ...

t of the may be and the subject of the subject of the subject of the subject of the subject of the subject of the subject of th 三、关于部分募集资金投资项目新增实施主体的议案 公司本次部分募投项目新增实施主体,符合公司实际经营需要,有利于推动 募投项目的顺利实施,不属于募投项目的实质性变更以及变相改变募集资金用途 的情形,不存在损害公司及全体股东特别是中小股东利益的情形,不会对公司生 产经营造成重大不利影响,审议程序符合相关法律法规和公司《募集资金管理制 度》、《公司章程》等有关规定。我们同意公司本次部分募投项目变更实施主体 的事项。 一、关于使用暂时闲置募集资金进行现金管理的议案 上海微创电生理医疗科技股份有限公司独立董事 关于第三届董事会第四次会议相关议案的独立意见 在保障募集资金安全的前提下,公司使用暂时闲置募集资金(含超募资金) 进行现金管理,用于购买安全性高、流动性好的理财产品或存款类产品。董事会 审议该议案的表决程序合法、有效,符合《上市公司监管指引第2号一上市公司 募集 ...

Financial Performance - The company reported a net profit of RMB 5,982,111.56 for the first quarter of 2023, primarily driven by non-operating income[6]. - The company reported a net loss of ¥9,326,097.49, compared to a net loss of ¥161,475.33 in the previous period, indicating a significant decline in profitability[15]. - The total operating profit was reported at -¥7,326,097.95, a substantial drop from -¥191,475.92 in the prior period[14]. - The total comprehensive loss for the period was ¥9,326,097.49, compared to a loss of ¥161,475.33 in the prior period[15]. - The net profit attributable to shareholders for Q1 2023 was -9,326,097.49 RMB, which is not applicable for comparison[45]. Assets and Liabilities - The total assets of the company as of March 31, 2023, amounted to RMB 1,794,906,439.62, showing a slight increase from RMB 1,788,331,481.27 at the end of 2022[11]. - The total current assets were reported at RMB 1,576,429,271.06, a slight decrease from RMB 1,595,986,425.47 in the previous year[11]. - The company's non-current assets increased to RMB 218,477,168.56 from RMB 192,345,055.80, reflecting a growth of about 13.6%[12]. - The total liabilities of the company as of March 31, 2023, were RMB 78,469,354.86, up from RMB 66,175,646.65, indicating an increase of approximately 18%[12]. - The total liabilities increased to ¥127,116,405.64 from ¥112,837,617.35, showing a growth of 12.6%[21]. - The company's capital reserve increased to ¥1,261,626,105.15 from ¥1,260,003,837.60, reflecting a slight growth of 0.1%[21]. Cash Flow - The company's cash and cash equivalents decreased to RMB 309,988,692.79 from RMB 584,887,873.89 in December 2022, representing a decline of approximately 47%[11]. - The cash inflow from operating activities in Q1 2023 was 72,661,826.96 RMB, compared to 65,483,818.29 RMB in Q1 2022[25]. - The cash outflow from operating activities was 86,449,337.51 RMB, up from 66,284,803.95 RMB in the same period last year[25]. - The company experienced a net cash outflow from investing activities of -¥258,807,625.67, compared to -¥2,879,395.77 in the previous period[17]. - The cash and cash equivalents at the end of the period were ¥302,819,817.79, down from ¥421,807,934.72, indicating a decrease of 28.1%[17]. Revenue and Expenses - The total revenue for Q1 2023 was 52,132,729.40 RMB, representing a decrease of 6.33% year-over-year[45]. - The total operating revenue for Q1 2023 was RMB 52,132,729.40, a decrease from RMB 55,658,087.32 in Q1 2022, representing a decline of approximately 9.1%[57]. - The total operating costs increased to RMB 66,593,648.07 in Q1 2023 from RMB 55,666,530.31 in Q1 2022, indicating a rise of about 19.6%[57]. - Research and development expenses increased to ¥23,452,627.63, up from ¥16,688,365.10, reflecting a 40.5% year-over-year growth[14]. - Research and development expenses totaled 27,001,815.48 RMB, accounting for 51.79% of operating revenue, an increase of 16.03 percentage points from the previous year[29]. - Sales expenses rose to ¥19,950,225.23, compared to ¥15,525,943.11, marking a 28.5% increase[14]. Market Strategy - The company is focusing on expanding its market presence and developing new technologies, although specific details were not disclosed in the report[4].

证券代码：688351 证券简称：微电生理 公告编号：2023-011 上海微创电生理医疗科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 19 日(星期三) 至 04 月 25 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investors@everpace.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 上海微创电生理医疗科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 29 日发布公司 2022 年度报告，并将于 2023 年 4 月 22 日发布公司 2023 年第 一季度报告，为便于广大投资者更全面深入地了解公司 2022 年度以及 2023 年第 一季度的经营成果、财务状况，公司计划于 2023 年 0 ...

Product Development and Innovation - The company received NMPA registration approval for two key products: the EasyStars™ disposable magnetic positioning catheter and the FireMagic® Cool 3D RF ablation catheter, breaking the import monopoly and filling a domestic gap in the atrial fibrillation treatment field[4]. - The company is advancing the development of the fourth-generation Columbus® 3D electrophysiological mapping system, which includes new features for automatic marking of ablation points and enhanced stability of pressure monitoring algorithms[4]. - The company has launched new products such as the OptimAblate® RF ablation system, designed for rapid arrhythmia ablation procedures, which integrates with the Columbus® system for real-time parameter sharing[9]. - The company is focusing on the development of high-precision catheters to enhance the accuracy and efficiency of treatment processes in electrophysiology[21]. - The company aims to enhance navigation precision and user experience through the integration of advanced technologies such as augmented reality in future product developments[85]. - The company has developed three core technology platforms in electrophysiology intervention and ablation treatment, focusing on image navigation, precision instruments, and energy therapy[170]. - The company has made breakthroughs in RF ablation and cryoablation technologies, improving product performance over imported counterparts[180]. - The company has integrated multi-channel temperature sensing technology, enhancing the safety of ablation procedures[180]. - The company has introduced a unique catheter product with dual magnetic sensors for precise positioning, enhancing surgical control[179]. - The company is committed to enhancing patient outcomes through the development of advanced medical technologies[164]. Financial Performance - The company achieved a revenue of 260 million yuan in 2022, representing a year-on-year growth of 36.99%[30]. - The net profit attributable to the parent company was 2.97 million yuan, marking a turnaround from loss to profit[30]. - The company's operating revenue for 2022 was ¥260,324,959.49, representing a 36.99% increase compared to ¥190,029,869.11 in 2021[45]. - The net profit attributable to shareholders for 2022 was ¥2,971,824.38, a significant recovery from a loss of ¥11,974,254.69 in 2021[45]. - The revenue after deducting non-core business income for 2022 was ¥257,519,752.42, up 35.96% from ¥189,410,755.10 in the previous year[45]. - The company reported a significant increase in revenue from equipment products, which surged by 265.60% to ¥41,670,815.94, although the gross margin decreased to 60.80%[148]. - The gross margin for medical devices was 69.71%, a decrease of 2.84 percentage points compared to the previous year[148]. - The company reported a total revenue of ¥161,069,000, with a net profit of ¥109,016,363.46, indicating a strong performance in the current period[191]. Market Presence and Sales Strategy - The company’s products are sold in over 700 terminal hospitals across 31 provinces in China and exported to 30 countries including France, Italy, and Spain[10]. - The company is positioned as one of the few manufacturers globally to provide a complete solution for three-dimensional cardiac electrophysiology devices and consumables[19]. - The company employs a sales model that combines equipment sales, deployment, and clinical support services to enhance market penetration[82]. - The company plans to expand its marketing network to increase market share and product penetration, leveraging existing customer resources[130]. - The company is focused on increasing its market share in the domestic market through new product launches and enhancing brand influence in the electrophysiology industry[137]. - The company aims to enhance its global sales network and brand recognition, striving to become an international medical device enterprise rooted in China[135]. Research and Development - The company has applied for 102 new patents globally, with 41 patents granted during the reporting period, enhancing its global patent portfolio[4]. - The company has achieved a total R&D investment of ¥95,717,561.34, representing a 6.27% increase compared to the previous year[187]. - The company has cumulatively invested ¥46,786,530.02 in the cryoablation catheter project, which is also awaiting NMPA registration in 2023[195]. - The company has reported a significant increase in R&D personnel compensation, totaling ¥5,228.23 million, compared to ¥4,335.39 million in the previous period[198]. - The company has developed a rapid 3D modeling algorithm for cardiac mapping, significantly reducing modeling time and improving intraoperative navigation[179]. Strategic Collaborations and Market Expansion - The company has established strategic collaborations for technology deployment in potential application areas, including partnerships for the development of magnetic navigation modules for the 3D mapping system[4]. - The company plans to deepen its focus on electrophysiology while expanding its product line and developing a comprehensive medical solution[135]. - The company plans to accelerate international expansion and strengthen group construction in response to new market opportunities and challenges[130]. - The company is committed to smart manufacturing to reduce production costs and improve efficiency in response to rising labor costs and management expenses[137]. Operational Risks and Governance - The management has outlined various operational risks and corresponding mitigation strategies in the report[36]. - The management emphasizes the importance of investor awareness regarding potential risks associated with forward-looking statements in the report[37]. - The company is enhancing its governance structure to ensure compliance with relevant laws and regulations, promoting efficient and stable operations[138].

Revenue and Profitability - Revenue for Q3 2022 reached ¥69,999,753.17, representing a 49.76% increase compared to the same period last year[9] - Net profit attributable to shareholders was ¥1,217,588.96, marking a turnaround from a loss in the previous year[9] - Basic earnings per share for Q3 2022 were ¥0.0029, reflecting profit growth driven by increased revenue[12] - Total operating revenue for the first three quarters of 2022 reached ¥191,907,793.27, a 39.7% increase from ¥137,356,717.52 in the same period of 2021[42] - Net profit for the third quarter of 2022 was ¥2,708,185.60, compared to a net loss of ¥5,502,186.98 in the same quarter of 2021[44] - Earnings per share for the third quarter of 2022 were ¥0.0066, recovering from a loss of ¥0.0138 per share in the same quarter of 2021[47] Expenses and Costs - R&D expenses totaled ¥25,768,251.35, accounting for 36.81% of revenue, a decrease of 8.69 percentage points year-on-year[12] - Total operating costs for the first three quarters of 2022 were ¥189,166,794.94, up 28.1% from ¥147,744,552.68 in 2021[42] - Research and development expenses for the first three quarters of 2022 were ¥53,577,900.37, compared to ¥42,840,189.71 in 2021, marking a 25.2% increase[42] Assets and Liabilities - Total assets increased by 165.99% to ¥1,779,072,710.93 compared to the end of the previous year[12] - Total current assets as of September 30, 2022, amounted to CNY 1,603,516,272.33, a significant increase from CNY 508,429,815.85 at the end of 2021, reflecting a growth of approximately 215.5%[33] - Cash and cash equivalents increased to CNY 1,354,608,802.07 from CNY 430,279,216.79, representing a growth of about 214.5%[33] - Total liabilities increased to ¥106,288,967.17 in 2022 from ¥79,212,380.32 in 2021, reflecting a growth of 34.2%[40] - Owner's equity totaled ¥1,672,783,743.76, significantly up from ¥589,633,396.45 in the previous year[42] - The company’s non-current liabilities rose to ¥37,322,949.57 from ¥32,506,145.52, indicating a 14.0% increase year-over-year[40] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥17,686,888.90, a decline of 210.39% due to increased raw material procurement costs[12] - Cash flow from operating activities for the first three quarters of 2022 was ¥214,314,609.50, an increase from ¥151,676,464.57 in 2021[47] - Net cash flow from operating activities was -$17.69 million, a decrease from $16.02 million in the previous period[51] - Total cash inflow from investing activities was $200.90 million, down from $281.06 million year-over-year[51] - Cash outflow from investing activities totaled $340.88 million, compared to $307.25 million in the previous period[51] - Net cash flow from financing activities was $1.08 billion, significantly higher than -$3.70 million in the previous period[53] - The ending balance of cash and cash equivalents was $1.35 billion, up from $432.25 million year-over-year[53] Shareholder Information - The number of shareholders at the end of the reporting period was 28,463, with the largest shareholder holding 34.94% of the shares[23] - The top ten shareholders collectively held 84.06% of the shares, indicating a high concentration of ownership[23] Market and Future Outlook - The increase in revenue was attributed to sustained growth in sales volume[19] - The company plans to continue expanding its market presence and investing in R&D to drive future growth[19] - The company has not disclosed any significant new strategies or market expansions during the reporting period[32] Other Financial Metrics - The company reported a total of ¥2,463,741.72 in non-recurring gains for the period, primarily from government subsidies[13] - The company reported a significant increase in accounts receivable, which rose to CNY 27,115,028.07 from CNY 26,373,531.16, reflecting a growth of about 2.8%[33] - The company has ongoing development expenditures amounting to CNY 65,003,816.96, up from CNY 51,364,267.51, indicating a focus on innovation and product development[37] - The company reported a significant increase in other income, totaling ¥3,220,346.65 in 2022, down from ¥7,388,912.19 in 2021[44] - The impact of exchange rate changes on cash and cash equivalents was $615,654.37, compared to $369,032.30 in the previous period[53]